Wilson and Waanders join London Healthcare franchise as Managing Directors
LONDON, September 26, 2017 – Bryan, Garnier & Co, the leading pan-European Investment Bank focusing on growth companies, is proud to announce two new experienced hires to join its European Healthcare division in London.
Dominic Wilson and Gary Waanders have together conducted more than 15 transactions and raised over £370m since early 2014 working on numerous IPOs and secondary fund raisings. They join Bryan, Garnier & Co as Managing Directors and are tasked with leveraging their combined experience in the UK market to further strengthen the bank’s already formidable footprint in the sector across Europe.
Dominic Wilson, British, has a held a variety of positions in the healthcare sector during his long career. He started his financial work as a Healthcare analyst based in New York, for Kleinwort Benson Securities and then moved on to hold numerous senior sales positions in the UK including Head of Sales at Old Mutual Securities, Piper Jaffray Ltd as Principal, European Equity Sales, Arden Partners and, more recently, Nomura Code as Head of Sales before joining Zeus in 2013 as Head of Healthcare Sales. Dominic has a BSc (Hons) in Genetics.
Gary Waanders, Australian, has a long experience of working in the life sciences and financial sectors. Since 2001 he has been an analyst in the City of London where he has previously worked as Director of Healthcare Research at Zeus Capital, Nomura Code Securities and KBC Peel Hunt. He has also worked in industry and academia including two years managing R&D teams at a small biotech company in Canada and six years as a Post-Doctoral Research fellow at the Ludwig Institute for Cancer Research (Lausanne Branch, Switzerland). He holds an MBA (Durham University, UK) and a PhD in Immunology from the Faculty of Medicine, Monash University, Melbourne (Australia).
Dominic Wilson and Gary Waanders comment, “We are delighted to join Bryan, Garnier & Co and to continue to work together. We have known and respected the firm for many years and regard it highly as the leading independent European investment bank specializing in growth companies, particularly in healthcare, a sector to which we and Bryan Garnier share a strong focus and commitment”.
Olivier Garnier, Managing Partner, comments: "I am pleased to welcome Dominic and Gary to our dedicated healthcare franchise, made up of over 20 senior professionals, to continue to build our business as the investment bank of choice for any European healthcare company. Our track record in M&A as well as growth financing built over 20 years of experience, is firmly established in the market.
We are also the most active independent investment bank involved in IPO‘s and follow-ons of European healthcare growth companies on Nasdaq, advising companies such as LDR, Celyad, DBV and Galapagos. Over the last three years, Bryan Garnier has completed over 14 transactions for European healthcare growth companies, raising a total of over $1 billion and including the sale of Symetis to Boston Scientific for $435 million last April".
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo and Reykjavik as well as New York and Palo Alto. The firm is a member of the London Stock Exchange.